title: A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus.
abstract: Chikungunya virus (CHIKV), a mosquito-transmitted alphavirus, recently reemerged in the Indian Ocean, India and Southeast Asia, causing millions of cases of severe polyarthralgia. No specific treatment to prevent disease or vaccine to limit epidemics is currently available. Here we describe a recombinant live-attenuated measles vaccine (MV) expressing CHIKV virus-like particles comprising capsid and envelope structural proteins from the recent CHIKV strain La Reunion. Immunization of mice susceptible to measles virus induced high titers of CHIKV antibodies that neutralized several primary isolates. Specific cellular immune responses were also elicited. A single immunization with this vaccine candidate protected all mice from a lethal CHIKV challenge, and passive transfer of immune sera conferred protection to naïve mice. Measles vaccine is one of the safest and most effective human vaccines. A recombinant MV-CHIKV virus could make a safe and effective vaccine against chikungunya that deserves to be further tested in human trials.
authors.affiliation: Unité de Génomique Virale et Vaccination, Institut Pasteur, CNRS URA 3015, 28 rue du Dr. Roux, 75724 Paris Cedex 15, France. samantha.brandler@pasteur.fr
authors.forename: Samantha
authors.initials: S
authors.lastname: Brandler
authors.forename: Claude
authors.initials: C
authors.lastname: Ruffié
authors.forename: Chantal
authors.initials: C
authors.lastname: Combredet
authors.forename: Jean-Baptiste
authors.initials: JB
authors.lastname: Brault
authors.forename: Valérie
authors.initials: V
authors.lastname: Najburg
authors.forename: Marie-Christine
authors.initials: MC
authors.lastname: Prevost
authors.forename: André
authors.initials: A
authors.lastname: Habel
authors.forename: Erich
authors.initials: E
authors.lastname: Tauber
authors.forename: Philippe
authors.initials: P
authors.lastname: Desprès
authors.forename: Frédéric
authors.initials: F
authors.lastname: Tangy
mesh_terms: D018354:Alphavirus Infections / Q000517:prevention & control*; D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D036022:Capsid Proteins / Q000276:immunology; D065632:Chikungunya Fever; D002646:Chikungunya virus / Q000276:immunology*; D002522:Chlorocebus aethiops; D003429:Cross Reactions; D007106:Immune Sera / Q000276:immunology; D007111:Immunity, Cellular; D007116:Immunization, Passive; D008458:Measles Vaccine / Q000276:immunology*; D051379:Mice; D008822:Mice, Transgenic; D014613:Vaccines, Attenuated / Q000276:immunology; D058425:Vaccines, Virus-Like Particle / Q000276:immunology*; D014709:Vero Cells; D014759:Viral Envelope Proteins / Q000276:immunology
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D036022:Capsid Proteins; D007106:Immune Sera; D008458:Measles Vaccine; D014613:Vaccines, Attenuated; D058425:Vaccines, Virus-Like Particle; D014759:Viral Envelope Proteins
keywords: Chikungunya; Measles; Vaccine; Virus-like-particles